In MDA-MB-231 cells, the percentage of G0/G1 stage cells in PGM2

In MDA-MB-231 cells, the percentage of G0/G1 stage cells in PGM2 group was 64.45 ± 1.39%, compared to blank control group and PG group(46.40 ± 1.88%, 48.90 ± 1.54%), the statistical difference was significant(P < 0.05). The percentage of S stage cells in PGM2 group was 25.99 ± 0.62%, compared to blank control group and negative group(35.14 ± 1.52%, 33.67 ± 1.32%), the statistical difference was significant, (P < 0.05). But in MCF-7 cells, the percentage of G0/G1 stage cells in blank control group, negative control group and PGM2 group were 51.25 ± 2.07%, 52.83 ± 1.76%, 55.75 ± 1.69%, and the percentage of S stage cells in blank control group, PG selleck group

and PGM2 group were 35.43 ± 1.52%, 34.88 ± 2.12%, 32.95 ± 2.29%, there were no statistically significant difference(P > 0.05). The results www.selleckchem.com/products/pp2.html indicated that, more MDA-MB-231 cells were blocked in G0/G1 stage after inhibiting MTA1 gene by pGenesil-1/MTA1

shRNA. Figure 7 Column diagram analysis for effect of inhibition MTA1 gene on cell cycle. 1-3: blank control group, PG group(empty vector), PGM2 group in MDA-MB-231 cells; 4-6: blank control group, PG group(empty vector), PGM2 group in MCF-7 IACS-10759 purchase cells. The results indicated that more MDA-MB-231 cells were blocked in G0/G1 stage after inhibition MTA1 gene by pGenesil-1/MTA1 shRNA plasmid(*P < 0.05), but in MCF-7 cells, there was no statistically significant difference of effect Vasopressin Receptor on cell cycle(P > 0.05). Discussion Breast cancer has the characteristics of powerful invasion ability and early metastatic property, which are the

primary reasons for failure in therapy. To research the molecular mechanisms for invasion and metastasis of breast cancer cells, as well as finding treatment target site, has significant meaning for improvement the prognostic outcome. Currently, researches that involved the gene such as MTA1, which were related to tumor metastasis, revealed that the expression level was closely related to the metastatic ability. MTA1 is a tumor metastasis associated candidate gene. It was cloned and selected from the 13762NF rat mammary adenocarcinoma cell lines with different spontaneous metastatic potentials by Toh et al in 1994[4]. the cDNA length of MTA1 was about 2.8 kb, encoded 703 amino acids and phosphoprotein of 80 kD. In 2000, Nawa et al[8] detected mta1 correlated series MTA1 in two breast cancer metastasis system, meanwhile, and found that MTA1 gene located on 14q32 of chromosome by antisense phosphorothioate oligonucleotides. Zhu X et al[9] found that overexpression of MTA1 was associated with tumor progression and clinical outcome in patients with NSCLC. MTA1 overexpression was detected in node-negative esophageal cancer and was significantly correlated with shorter disease-free interval[10]. It’s indicated that MTA1 gene involved in the critical molecule mechanism of tumor infiltration and metastasis.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>